Palvella's 15min chart triggered MACD Death Cross, Bearish Marubozu

According to the 15-minute chart for Palvella, a significant technical indicator known as the MACD Death Cross has been triggered, accompanied by a bearish Marubozu candle at 09/18/2025 15:00. This suggests that the stock price is likely to continue falling in the short term, as sellers are currently dominating the market and bearish momentum is expected to persist.

Palvella Therapeutics (PVLA) has recently experienced a significant technical indicator known as the MACD Death Cross, accompanied by a bearish Marubozu candle on September 18, 2025, at 15:00 9 of the Fastest-Growing Biotech Stocks Under $10 Billion^[1]. This combination of indicators suggests that the stock price is likely to continue falling in the short term, as sellers currently dominate the market and bearish momentum is expected to persist.

The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a potential reversal in the stock's trend. The Marubozu candle, characterized by no wicks and a single candle body, signals strong selling pressure. These indicators together suggest a strong bearish sentiment in the market.

Investors should closely monitor Palvella Therapeutics' stock price and other technical indicators to assess the potential impact on the company's valuation. The recent publication of a manuscript in Lymphatic Research and Biology, which highlights the unmet clinical need for venous malformations and the potential of rapamycin as a targeted therapy, may not be sufficient to offset the current bearish sentiment Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy^[2].

Palvella Therapeutics' Phase 2 TOIVA trial with QTORIN™ 3.9% rapamycin anhydrous gel is expected to release top-line data in mid-December 2025. The success of this trial could provide a significant catalyst for the stock price, potentially reversing the current bearish trend.